Therapeutic potentiation of the immune system by costimulatory Schiff-base-forming drugs

Abstract

IMMUNE responses are orchestrated by CD4 T lymphocytes, which receive a cognitive signal when clonally distributed receptors are occupied by major histocompatibility complex (MHC) class II-bound peptides on antigen-presenting cells (APCs)^1,2. The APCs provide costimulatory signals, through macromolecules such as CD80, that regulate outcomes in terms of T-cell activation or anergy^3–6. We have studied essential complementary chemical events in the form of Schiff base formation between carbonyls and amines that are constitutively expressed on presenting cell and T-cell surfaces^7–9 and provide a new target for manipulation of immune responses10,11. Here we show that small Schiff base-forming molecules can substitute for the physiological donor of carbonyl groups and provide a costimulatory signal to CD4 Th-cells through a mechanism that activates clofilium-sensitive K⁺ and Na⁺ transport. One such molecule, tucaresol, enhances CD4 Th1-cell responses, selectively favouring a Thl-type profile of cytokine production. In vivo tucaresol potently enhances CD4 Th-cell priming and CDS cytotoxic T-cell priming to viral antigens, and has substantial therapeutic activity in murine models of disease.